2 doctors (Gangadharan VP + Abi Abraham M) generate ₹84.8 Cr = 20.7% of total hospital revenue. Top 5 doctors = 33.7% of revenue. Concentration is lower than FY24 (was 27.4%), but Gangadharan VP at ₹52.9 Cr (12.9%) remains the single biggest key-person risk.
Revenue by Department — Top 15 (₹ Crore, FY25)
Nephrology + Medical Oncology = 30.3% of total revenue
Revenue Mix
IP ₹298 Cr · OP ₹99 Cr · Pharmacy ₹34 Cr
IP Revenue
₹298 Cr
OP Revenue
₹99 Cr
Pharmacy
₹34 Cr
Registration
₹7.3 Cr
Top 12 Doctors by Revenue (₹ Crore, FY25)
Top 12 = 63.6% of all doctor revenue
Revenue Concentration Curve (Lorenz)
X = cumulative doctor count · Y = % of total revenue
Department Performance Table — All 22 Departments
Click column headers to sort. ALOS computed from bed utilisation. Pharma/Diag are estimates.
#
Department
Total ₹Cr
% Share
IP ₹Cr
OP ₹Cr
Pharma ₹Cr
Diag ₹Cr
IP Disc.
OP Visits
ARPP-IP
ARPP-OP
ARPOB
ALOS
Docs
Tier
Revenue Composition by Department — IP · OP · Pharma · Diagnostics
Pharma and Diagnostics are estimates based on specialty benchmarks
Top 6 Department Doctor Breakdowns
Medical Oncology
Nephrology
GI Surgery
Neuro Surgery
Gastroenterology
Cardiology
Filter:
#
Doctor
Department
Total ₹Cr
% Hosp
IP ₹Cr
OP ₹Cr
Discharges
Bed Days
OP Visits
ARPP-IP
ARPOB
ARPP-OP
BCG
🚨 Concentration Risk — FY25 Verified Figures
Top 2 doctors (Gangadharan VP + Abi Abraham M): ₹84.8 Cr = 20.7% of hospital revenue |
Top 5 doctors: ₹138.2 Cr = 33.7% of revenue |
80% revenue threshold: reached at Top 24 doctors out of 177 |
Single-doctor depts: Medical Oncology (Gangadharan 100%), Urology (George P Abraham 100%), Min. Invasive Surgery (Padmakumar 100%), CT Surgery (Sujith 100%), Psychiatry (Xavier Pulikkal 100%)
Revenue Concentration — Pareto (Doctors)
Red dashed line = 80% cumulative threshold · Top 24 of 177 doctors = 80% of revenue
Single-Doctor Dependency by Department
% of dept IP revenue from top-1 doctor. Red > 70% = critical risk · 10 of 15 major depts are single-doctor dependent
Revenue-at-Risk — Top 5 Doctor Departure Scenario
Estimated annual revenue impact if doctor were to leave
Department Depth Index (Multi-Doctor Resilience)
Score = 10 − (top doctor % / 10). Higher = more resilient
X-Axis:Y-Axis:
Volume vs ARPP-IP — Department Portfolio Matrix
Bubble size = total revenue. Axes = median lines. Quadrant = BCG category
⭐ Stars — High Volume + High ARPP-IP
💠 Premium — Low Volume + High ARPP-IP
💰 Cash Cows — High Volume + Low ARPP-IP
❓ Question Marks — Low Volume + Low ARPP-IP
Monthly Revenue — IP vs OP (₹ Crore, FY25)
IP typically 73-75% of monthly revenue. Peak in March (Q4).
Top 5 Departments — Monthly IP Revenue Trend
Proportional allocation from monthly IP totals
IP Discharge & Bed Occupancy — Monthly
Discharge count (left axis) vs Occupancy % (right axis)
Payor Mix — FY25
Cash at 70% (₹288 Cr), Insurance 24% (₹97.5 Cr), Government 3.5% (₹14.3 Cr), Corporate 2.4% (₹9.9 Cr). Insurance grew from 22% in H1 to 26% by Q4 — momentum building.
ARPP-OP by Department (₹ per visit)
Computed from OP Revenue / OP Visits. All in ₹ per visit.
ARPOB by Department (₹ per occupied bed day)
Computed from IP Revenue / Occupied Bed Days. Higher = better bed monetisation.
Total refunds = ₹1.57 Cr. Med Oncology: ₹36.9L refunds (0.7%). Gastroenterology: ₹11.1L. Signals billing errors or tariff disputes.
Root cause analysis of top 20 refund events per department. Identify billing system gaps. Pre-auth for high-value procedures. Target: reduce refunds by 30%.
Revenue Cycle + HODs
+₹40–50L
Medium
45–75
ALOS Optimisation — Nephrology & Psychiatry
Nephrology ALOS = 8.8 days (peer benchmark 6–7d). Psychiatry ALOS = 12.4 days. Each 1-day ALOS reduction in Nephrology frees ~450 bed days = ₹1.6 Cr throughput gain at current ARPOB.
Implement clinical pathway reviews for Nephrology top DRGs. Establish discharge planning from Day 1 of admission. Weekly LOS monitoring by consultant.
HOD Nephrology + Clinical Ops
+₹1.5–3 Cr
Medium
45–75
OP-to-IP Conversion — Endocrinology & Dermatology
Endocrinology: 12,105 OP visits, only 41 admissions (0.3% conversion). Dermatology: 13,187 OP visits, 59 admissions (0.4%). Both are chronic disease specialties with high admission potential.
Set up dedicated IP admission protocol for chronic cases. Coordinate with Nephrology for diabetic nephropathy pathway. Dermatology: target psoriasis/autoimmune inpatient program. Target: 1% conversion = ~240 additional admissions.
HOD Endocrinology + Dermatology
+₹1–2 Cr
Medium
60–100
Revenue Seasonality Smoothing
Oct–Nov revenue trough = ₹30.7–31.3 Cr vs Jan peak of ₹36.78 Cr. ₹6.0 Cr variance annually. Occupancy dips in lean months.
Introduce packages for preventive health checks, elective procedures, and wellness programs specifically timed for Q2–Q3. Corporate tie-ups for annual health screenings. Target: reduce trough-to-peak variance by 30%.
Marketing + Business Dev
+₹1–2 Cr
Medium
75–100
Payor Mix — Insurance Quick Wins
Insurance = 24% of revenue (₹97.5 Cr) vs Cash 70% (₹288 Cr). Apollo at 45% insurance. ₹73 Cr gap vs peer benchmark at current revenue scale.
Fast-track empanelment with 5 top TPAs not yet on panel. Assign dedicated TPA coordinator. Target pre-auth turnaround <4 hours. Set up insurance help desk at registration.
CFO + Revenue Cycle
+₹3–5 Cr
Medium
💰 Total 100-Day Recoverable Revenue Estimate
Conservative: ₹8–12 Cr | Optimistic: ₹14–20 Cr | All zero-to-low capex. Discount discipline alone (₹1–1.5 Cr) and pharmacy leakage (₹5–8 Cr) are the two biggest wins. These flow directly to EBITDA margin improvement.
📋 FY25 Budget vs Actual Performance
Revenue Achievement
85.3%
₹409.7 vs ₹480.3 Cr budget
Revenue Shortfall
-₹70.6 Cr
Gap widened in H2
IP Disc Achievement
82.3%
21,023 vs 25,555 budget
OP Visit Achievement
90.3%
3,74,796 vs 4,15,087 budget
Best Month
May
100.2% — only month at/above budget
🚨 Budget Shortfall Analysis
FY25 achieved only 85.3% of ₹480 Cr revenue budget. The gap widened from H2: Oct 84.5%, Nov 82.3%, Dec 84.2%, Feb 71.7% (worst month). IP discharges at 82.3% (21,023 vs 25,555) is the primary driver — occupancy averaged 52% vs 63% budgeted. The budget assumed aggressive ramp-up that didn't materialize. OP visits at 90.3% performed better, suggesting demand exists but IP conversion is the bottleneck.
How ₹410 Cr grows to ₹550 Cr: leakage plug + organic + strategic expansion
Specialty Growth Opportunity Matrix
Bubble size = current revenue. Position = growth potential vs investment required.
Strategic Growth Action Plan — Phase 2
Sequenced by revenue impact. Each initiative has a clear data-backed rationale from FY25 actuals.
Priority
Initiative
FY25 Baseline
Key Data Signal
Action
Rev Impact
Timeline
P1
Oncology Scaling
₹53.5 Cr dept, 5,007 disc
Highest volume dept. No LINAC on campus — radiation patients referred out. Each referred case = ₹1–3L lost.
Commission LINAC. Recruit 2nd oncologist. Target 7,000 disc/yr by FY27. Expand Radiation Oncology from ₹5.30 Cr to ₹20 Cr+.
+₹25–35 Cr
6–18 months
P1
Liver Transplant Programme
₹13.64 Cr, 265 disc
ARPP-IP = ₹4.79L — highest in hospital. Only 265 discharges vs potential 600+. Each transplant = ₹8–15L.
Add 2nd hepatologist. Expand dedicated liver ICU from 6 to 12 beds. Pan-India patient referral network. Target 500+ disc/yr.
+₹20–30 Cr
3–9 months
P2
Insurance Penetration
24% insurance mix (₹97.5 Cr)
Cash 70% vs Apollo 45%. ₹73 Cr gap to peer benchmark. Each 5% shift from cash to insurance = ₹8–10 Cr incremental at better ARPP.
Empanel 10+ new TPAs. Dedicated insurance coordinator. Pre-auth automation. Corporate wellness contracts. Target: 40% insurance by FY27.
+₹18–25 Cr
6–12 months
P2
Nephrology BMT Expansion
₹54.97 Cr, ARPP-IP ₹3.05L
Top revenue dept. ALOS 8.8d (above peers). BMT programme would attract high-complexity, high-ARPP cases. Bone marrow transplant = ₹15–25L per case.
BMT unit setup (₹35 Cr capex). Target 50 BMT cases/yr in Year 1, 150 by Year 3. Reduce general nephrology ALOS by 2 days through clinical pathways.
+₹15–20 Cr
12–24 months
P2
GI Surgery Robotic Programme
₹27.19 Cr, ARPP-IP ₹2.00L
ARPP-IP ₹1.96L is strong but ALOS 6.4d is high. Robotic surgery reduces ALOS by 1.5–2d and commands 20–30% premium on procedure fees.
Acquire robotic surgery system. Credential 2 surgeons. Target 300 robotic procedures/yr. Reduces ALOS and attracts premium payers.
+₹10–15 Cr
6–12 months
P2
ARPOB Improvement Programme
₹31,898/day vs Apollo ₹60,588
₹28,690/day gap to Apollo. Each ₹5K ARPOB improvement across 89,585 bed-days (ARPOB ₹33,414) = ₹4.48 Cr. Case mix upgrade is the primary lever.
Reduce low-ARPP admissions (Psychiatry ₹52K ARPOB, Gen Medicine ₹14K). Grow high-ARPP beds (Liver ₹63K, Nuclear Med ₹46K, Nephrology ₹35K). Target ₹38K ARPOB by FY27.
+₹5–10 Cr
12–18 months
P3
Nuclear Medicine & PET-CT
₹1.66 Cr, 113 admissions
ARPOB ₹46K — 2nd highest in hospital. 329 OP visits but nearly zero admissions. PET-CT is a natural feeder for Oncology pathway.
Dedicate PET-CT slot for Oncology patients. Integrate Nuclear Med into cancer care bundles. Target 600+ PET-CT scans/yr. Partner with Radiation Oncology for DOTATATE therapy.
+₹5–8 Cr
6–12 months
P3
ENT Expansion
₹3.89 Cr, 8,116 OP visits
8,116 OP visits but only 322 admissions (3.8% conversion). Strong OP demand not converting. Cochlear implants = ₹3–5L per case.
Add cochlear implant programme. Expand ENT theatre capacity. Target 500+ admissions/yr. ENT OP-to-IP conversion target: 6%.
+₹3–5 Cr
6–12 months
⚠️ Key Risk Register
Top 5 Risks to Revenue Plan
Risk
Current Exposure
Probability
Mitigation
Key Person — GANGADHARAN VP
₹52.9 Cr = 12.9% of revenue
High
Recruit 2nd oncologist. Build department not person. Implement succession plan.
Key Person — ABI ABRAHAM M
₹31.9 Cr = 7.8% of revenue
High
BMT programme reduces single-doctor dependency in Nephrology.
Insurance Claim Rejections
₹1.57 Cr refunds; unclear rejection rate
Medium
Pre-auth automation. Daily TPA rejection tracker. Revenue cycle team.
ALOS vs Bed Capacity
Nephrology ALOS 8.8d blocks beds
Medium
Clinical pathway implementation. Early discharge planning protocol.
Q3 Revenue Dip
Apr/Jun ₹6 Cr below peak
Low
Preventive health packages, corporate screenings in lean months.
Implementation Dashboard — 100-Day Tracker
Initiative
Target
Metric
Status
Discount policy
Day 15
ED discount <5%
Not started
Doctor discount matrix
Day 15
Top-10 doc disc <1%
Not started
OB & Gynec rate card
Day 30
Disc <2%
Not started
Pharmacy capture
Day 45
OPD Rx capture >80%
Not started
Refund root cause
Day 60
Refunds <₹1 Cr/yr
Not started
Nephrology ALOS
Day 75
ALOS <8.5d
Not started
TPA empanelment
Day 100
5 new TPAs
Not started
Endocrinology OP-IP
Day 100
Conversion >1%
Not started
LHRC ARPOB
₹33.4K/day
vs Apollo ₹60.6K · gap ₹27.2K
LHRC Occupancy
52%
vs Apollo 68% · IHH 72% · 470 beds
LHRC ALOS
4.3 days
vs Apollo 3.32d · IHH 4.2d
LHRC EBITDA (target)
19%
vs Apollo 24.6% · IHH 18%
LHRC ARPP-IP
₹1.42 L
vs Apollo ₹1.73 L · gap ₹31,000
Insurance Mix
24%
vs Apollo 45% · IHH 35%
ARPOB — ₹/Occupied Bed/Day
Gap: LHRC ARPOB ₹33,414 is 45% below Apollo ₹60,588. Closing to ₹38K would add ~₹5.7 Cr annually at current bed days.
Bed Occupancy Rate (%)
Gap: 13-18 ppt occupancy gap vs peers. Each 5 ppt improvement = ~8,600 occupied bed days = ~₹2.7 Cr at ARPOB ₹33,414.
ALOS — Average Length of Stay (Days)
Near parity: LHRC 4.3d vs IHH India 4.2d vs Apollo 3.32d. Oncology and Nephrology long stays pull the average up.
Specialty Mix vs Apollo — % of IP Revenue
Insight: LHRC Nephrology at 17.4% is unusually high. Apollo shows Neuro 10% and Gastro 10% — both growth opportunities for LHRC.
Payor Mix — LHRC vs Apollo vs IHH
EBITDA Margin (%)
Apollo's playbook: Reached 24.6% by (1) upgrading case mix, (2) reducing ALOS, (3) expanding pharmacy. LHRC at 19% target — same levers available.
Detailed Benchmark Comparison Table
Metric
LHRC FY25
IHH India FY25
Apollo FY25/H1FY26
LHRC Gap vs Apollo
Operational Beds
471
5,008 (28 hospitals)
8,025 (45 hospitals)
Different scale
Occupancy Rate
52%
72%
68%
▼ 15.3 ppt
ALOS (days)
4.3
4.2
3.32
▲ 1.5d longer
ARPOB (₹/day)
₹33,414
~₹47,100
₹60,588
▼ ₹33,903
ARPP-IP
₹1.42 L
~₹1.96 L (RM 9,902)
₹1.73 L
▼ ₹44,000
EBITDA Margin
~19% (target)
18%
24.6%
▼ 5.6 ppt
Insurance % (Payor)
24%
~35%
45%
▼ 19 ppt
Revenue Growth YoY
~12% (plan)
13% (FY25)
9-10%
On track
📋 Department / Doctor MIS — Monthly Breakdown
Select a doctor to view month-wise IP Revenue, OP Revenue & KPIs · Amount in Lakhs · Source: Performance Report · Kochi FY25
Department
Doctor
Search
IP Revenue — Monthly (₹ Lakhs)
OP Revenue — Monthly (₹ Lakhs)
Total Revenue — Monthly (₹ Lakhs)
Revenue (₹ Lakhs)
OP & IP monthly billing · Taxable Amt basis · Kochi
Month
OP Rev (L)
IP Rev (L)
Total (L)
ARPP(OP)
ARPP(IP)
ARPOB
IP Discharge
Month
IP Discharge
Bed Days
ALOS
OP Visit
Month
New
Free
Revisit
Total
ADOP
All Doctors — FY25 Annual Summary (click any row to load detail)